Revenue segments as reported by the company.

Cannabis revenue

Distribution revenue

Beverage alcohol revenue

Wellness revenue

Adult-use

Canada - Medical

International - Medical

Bulk

Hemp

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Impairment of Assets

Litigation settlement

Transaction costs

Change in fair value of contingent consideration

Restructuring costs

Other than temporary change in fair value of convertible notes receivable

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Tilray Brands

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Tilray Brands reports record revenue and optimistic outlook for 2025

Tilray Brands achieved remarkable financial performance in Q4 2024, driven by strategic acquisitions and a focus on innovation. Despite challenges like price compression, the company remains optimistic about future growth opportunities. Tilray's commitment to quality products and innovation positions it well for continued success in the market.

Tilray Brands reports record Q1 revenue growth and global expansion

Tilray Brands delivered a robust performance in Q1 2025, showcasing strong revenue growth, margin improvement, and strategic expansion across its diversified product portfolio.
While facing challenges in a competitive landscape and evolving regulatory environment, Tilray's financial strength, international growth initiatives, and focus on innovation position it well for future success.
By capitalizing on opportunities in wellness products, expanding into new beverage categories, and leveraging strategic partnerships, Tilray is poised for continued growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution Business segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage Alcohol Business segment refers to the production, marketing, and sale of beverages. The Wellness Business segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

MedMen Enterprises Inc.

MedMen Enterprises Inc. (OTCQX:MMNFF) revealed Tuesday that it has secured $100 million in financing  via a private sale of its units in a deal led by Serruya Private Equity. At the same time, the company disclosed that Tilray, Inc. (NASDAQ:TLRY) acquired the majority of MedMen's outstanding senior secured convertible notes that were originally held by certain funds affiliated with Gotham Green Partners LLC (GGP) and others.

Analyst Says MedMen's Momentum Changing, Tilray's Stake Won't Double Its Value But Will Hold Premium

Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.

Do Options Traders Know Something About Tilray (TLRY) Stock We Don't?

MedMen runs more than 25 stores in six states, including California, the world's largest cannabis market.

Tilray jumps after $166 million deal for stake in MedMen to step into the US retail cannabis market

After U.S. markets closed Tuesday, pot grower Tilray Inc. (NASDAQ: TLRY) announced that it had acquired a majority of the outstanding senior secured convertible notes of MedMen Enterprise.

How Tilray Is Breathing Life Into Pot Stocks

Cannabis retailer MedMen Enterprises Inc. (CSE:MMEN) (OTCQX:MMNFF) has secured $100 million in financing through a private placement of its units. Investors, led by Serruya Private Equity, agreed to purchase $100 million of the Los Angeles-based company's units at a purchase price of $0.24 per unit.

MedMen Announces $100M Equity Investment On Heels Of Tilray Buying Its Convertible Debt, Deal Led By Serruya Private Equity

Tilray Inc (NASDAQ:TLRY) is trading higher Wednesday after the company announced that it acquired the majority of the outstanding senior secured convertible notes of MedMen Enterprises Inc (OTCQX:MMNFF) for about $165.8 million. The acquisition provides Tilray with a path to obtain a significant equity position in MedMen through conversion of the notes and exercise of associated warrants following U.S. cannabis legalization.

Why Tilray Shares Are Trading Higher Today

Amplify Seymour Cannabis ETF

Cronos Group

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

Amplify Alternative Harvest ETF

Amplify US Alternative Harvest ETF

AdvisorShares Pure US Cannabis ETF

Global X Cannabis ETF

Trulieve Cannabis Corp.

AXS Cannabis ETF

Cambria Cannabis ETF

AdvisorShares Vice ETF

AdvisorShares Pure Cannabis ETF 

Julian Lin's Highest Conviction Idea (Ever)? Cannabis. (Podcast)

The shares of Tilray, Inc. (Nasdaq: TLRY) increased by over 8% pre-market. This is why it happened.

Tilray Shares Increase Over 8% Pre-Market: Why It Happened

Altria

Candian cannabis giant Tilray, Inc. (NASDAQ: TLRY) announced Tuesday it has acquired the majority of the outstanding senior secured convertible notes of MedMen Enterprises Inc. (CSE:MMEN) (OTCQX: MMNFF) that were originally held by certain funds affiliated with Gotham Green Partners, LLC and other funds. The transaction is valued at $165.8 million.

Cantor Fitzgerald Says Tilray's Stake In MedMen One Of The Steps In The 'U.S.' Journey, Could Be Getting Close To Altria

It'll need to demonstrate its potential first.

Is Tilray a Warren Buffett Stock?

Tilray's investors cheered after it posted a profit in the fourth quarter, but is that the only reason to buy?

Is Tilray's Stock a Smart Buy After Its Q4 Earnings?

Tilray shares rose in extended trading Tuesday after it announced it acquired a majority stake in Medmen for $165.8 million.

Cannabis company Tilray acquires majority stake in Medmen in bet on U.S. legalization

Tilray, Inc. ("Tilray") (TSX:TLRY), and MedMen Enterprises Inc. ("MedMen") (CSE:MMEN) (OTCQX:MMNFF), announced on Tuesday that Tilray has acquired the majority of MedMen's outstanding senior secured convertible notes that were originally held by certain funds affiliated with Gotham Green Partners, LLC (GGP) and others. What's In It For Tilray?

Tilray Acquires Majority Position in Amended MedMen Convertible Notes, Accelerating Tilray's Path Into U.S. Cannabis Market When, Not If, Federal Legalization Occurs

Tilray Inc (NASDAQ:TLRY) shares are trading higher following news the company purchased a majority position in amended MedMen convertible notes for about $165.8 million. Irwin D. Simon, Tilray's Chairman and CEO, said, "Backed by accelerating trends towards legalization globally, we are focused on building the world's leading cannabis-focused consumer branded company with a goal of $4 billion of revenue by the end of our fiscal 2024.

Why Tilray's Stock Is Trading Higher After Hours

Canadian cannabis company Tilray Inc. has its eyes on the U.S.

Tilray eyes U.S. cannabis market with MedMen move, stock gains in late trading

Agrify

Scotts Miracle-Gro

Alan Brochstein, a friend of the podcast and now a 3peat guest, is the founder of 420 Investor and New Cannabis Ventures. Thoughts on uplisting, the ETF MSOS, volume and valuation issues and confronting the California cannabis landscape.

Alan Brochstein: The Longer Legislation Takes, The Better For Cannabis Companies (Podcast Transcript)

Aurora Cannabis

Village Farms International

Canadian Marijuana Stocks For Your List This Week The post Best Canadian Marijuana Stocks For Your List Right Now appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Best Canadian Marijuana Stocks For Your List Right Now

Apple

Microsoft

Shopify

British Columbia Investment Management raised stakes in Apple, Microsoft, and Shopify, and initiated a stake in marijuana stock Tilray in the second quarter.

Huge Pension Makes Big Bets in Apple, Microsoft, Shopify, and Tilray Stock

Canopy Growth

WM Technology

Earnings, consolidation, technicals and the macro layout should all be on cannabis investors' radars heading into the fourth quarter, Tim Seymour says.

Four things to watch in the cannabis market amid earnings season, possible legislation

GrowGeneration Corp

SNDL Inc.

Cipher Pharms Inc (OTC:CPHRF) shares closed up 20.19% at $1.62 with an estimated market cap of $43,398,257. 22nd Century Group (AMEX:XXII) shares closed up 9.92% at $4.03 with an estimated market cap of $649,314,577.

Bearish Wave Dumps Marijuana Stocks - GrowGeneration Sundial Growers And Aurora Cannabis Among Top Cannabis Movers For Today - Tilray Down By 6%

2 Marijuana Stocks To Watch Before Friday The post Best Cannabis Stocks To Buy? 2 To Watch This Month appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Best Cannabis Stocks To Buy? 2 To Watch This Month

TLRY stock currently reflects unrealistic assumptions about its growth and about the chances of legalization in the United States. The post Tilray Stock Is Probably Overvalued At This Price appeared first on InvestorPlace.

Tilray Stock Is Probably Overvalued At This Price

All of them are more important than market cap -- another front where Canopy tops Tilray.

3 Ways That Canopy Growth Beats Tilray

The last several years will definitely be remembered as the most important for cannabis-related industries, as various milestones have been achieved. So far, around 18 states and Washington, DC, have legalized adult-use marijuana, and 37 have given the green light to medical cannabis programs.

As The Cannabis Industry Blossoms, So Do CEO Paychecks, M&A Deals Extremely Lucrative For Execs In High Places

GW Pharmaceuticals

Alan Brochstein: The Longer Legislation Takes, The Better For Cannabis Companies (Podcast)

News for Tilray Brands Stock (TLRY)